PARP inhibitors

IDrugs

Volumn 4, Issue 7, 2001, Pages 804-812

  Li, Jia He ^a   Zhang, Jie ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001176135     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Burkel A, Schreiber V, Dantzer F, Oliver FJ, Niedergang C, deMurcia G, Menissier-deMurcia J: Biological significance of polyfADPribosyl)ation reactions: molecular and genetic approaches. In: From DNA damage and stress signaling to cell death. Murcia GD, Shall S (Eds) Oxford University, USA (2000):180-124.
2. Burkle A: Poly(APDribosyljation, a DNA damage-driven protein modification and regulator of genomlc instability. Cancer Lett (2001) 163:1-5.
3. Smith S: The world according to PARP. Trends Biochem Sei (2001) 26:174-179.
4. Zhang J: PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries. In Emerging Drugs: The Prospect for Improved Medicines (1999). Fitzgerald JD, Bowman WC, Taylor JB (Eds) Ashley Press, London (1999) 4:209-221.
5. Ha HC, Snyder SH: Poly(ADP-ribose) polymerase1 in the nervous system. Neurobiol Dis (2000) 7:225-39.
6. Banasik M, Ueda K: Inhibitors and activators of ADP-ribosylation reactions. Mol Cell Biochem ( 1994) 138:185-197.
7. Zhang J, Li J-H: Poly(ADP-ribose) polymerase inhibition by genetic and pharmacological means. In: Cell Death. Szabo C (Ed), CRC Press, Boca Raton (2000):279-304.
8. Curtin NJ, Golding BT, Griffin RJ, Newell DR, Roberts MJ, Srinivasan S, White AW: New poly(ADP-ribose) polymerase Inhibitors for chemo- and radiotherapy of cancer. In: From DNA damage and stress signaling to cell death. Murcia GD, Shall S (Eds) Oxford University Press, USA (2000):177-206.
9. Ruf A, deMurcia G, Schulz GE: Inhibitor and NAD binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry (1998) 37:3893-3900.
10. Shinkwin AE, Whish WJD, Threadgill MD: Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H}-ones and preliminary evaluation as inhibitors of poly(ADP-ribose) polymerase (PARP). Bioorg Med Chem( 1999) 7:297-308.
11. Watson CY, Whish WID, Threadgill MD: Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose) . polymerase (PARP). Bioorg Med C/7em(1998) 6:721-734.
12. Suto MJ, Turner WR, Arundel-Suto CK, Werbel LM, Sebolt-Leopold JS: Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anti-Cancer Drug Des (1991) 7:107-117
13. Farkas B, Sumegi B, Csete B, Szekeres G: Novel poly(ADP)-ribose polymerase inhibitor with photoprotective activity. J Invest Dermatol (1999)113:444.
14. Milam KM, Cleaver JE: Inhibitors of poly(adenosine diphosphateribose) synthesis effect on other metabolic processes. Science (1984)223:589-591.
15. Cleaver JE: Differential toxicity of 3-aminobenzamide to wild-type and 6-thioguanine-resistant Chinese hamster cells by interference with pathways of purine biosynthesis. Mutât Res (1984) 131:123127.
16. Griffin RJ, Srinivasan S, White AW, Bowman K, Calvert AH, Curtin NJ, Newell DB, Golding BT: Novel benzimidazole and quihazolinone Inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Pharm Sei (1996) 2:43-47. '
17. Griffin RJ, Srinivasan S, Bowman K, Calvert AH, Curtin NJ, Newell DR, Pemberton LC, Golding BT: Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone Inhibitors of the DMA repair enzyme poly(ADP-ribose) polymerase (PARP). J MedChem (1998) 41:5247-5256.
18. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ: Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU 1025 and NU 1064. Br J Cancer (1998) 78:1269-1277.
19. Parveen I, Naughton DP, Whish WJD, Threadgill MD: 2Nitroimidazole-5-ylmethyl as a potent bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. Bioorg Med Chem Lett (1999) 9:2031-2036.
20. White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, Maegley K, Newell DR, Srinivasan S, Golding BT: Resistancemodifying agents. 9. synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme po!y(ADPribose) polymerase. J Med Chem (2000) 43:4084-1097.
21. Curtin NJ, Calvert AH, CananKoch S, Durkacz BW, Griffin RJ, Golding BT, Hostomsky Z, Kyle S, U J, Maegley K, Newell DR, Wang LZ, Webber SE, White A, Yu XH: Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clin Cancer Res (2000) 6(Suppl):205.
22. Calabrese CR, Curtin NJ, CananKoch SE, Batey MA, Thomas HD, Kyle S, Wang LZ, Boritzki TJ, Webber SE, Griffin RJ, Golding BT, Hostomsky Z, Calvert AH, Newell DR: Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clin Cancer Res (2000) 6(Suppl):150.
23. Li J-H, Serdyuk L, Ferraris DV, Xiao G, Tays KL, Kletzly PW, U W, Lautar S, Zhang J, Kalish VJ: Synthesis of substituted 5[Hjphenanthridin-6-ones as potent poly(ADP-ribose) polymerase1 (PARP1) inhibitors. Bioorg Med Chem Lett (2001) in press.
24. Banasik M, Komura H, Shimoyama M, Ueda K: Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem (1992) 267:1569-1575.
25. Soriano FG, Virag L, Jagtap P, Szabo, E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KGK, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfuntion: the role of poly(ADP-ribose) polymerase activity. Nature Med (2001) 7:108-113.
26. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dimagl U, Szabo C, Endres M: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in vitro and in vivo models of stroke. Int J Mol Med (2001) 7:255-260.
27. Zhang J, Li J-H, Lautar, S: Post-ischemia protection by a potent PARP inhibitor in transient focal cerebral ischemia. Soc Neurosci Abstr(\998) 24:1226.
28. Walles T, Piepper AA, Li J-H, Zhang J, Snyder, SH, Zweier JL: Demonstration that accumulation occurs in the postischemic heart and is associated with myocardial necrosis. Circulation (1998) 98:Suppl I-60.
29. LaPlaca MC, Zhang J, Raghupathi R, Smith F, Bareyre FM, U J-H, Graham Dl, Snyder SH, Mclntosh TK: Pharmacologie inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. J Neurotrauma (1999) 16:976.
30. Mazzon E, Dugo L, deSarro A, Li J-H, Caputi AP, Zhang J, Cuzzocrea S: Beneficial effects of GPI 6150, an inhibitor of poly (ADP-ribose) polymerase, in a rat model of splanchnic artery occlusion and reperfusion. Shock (2001) in press.
31. Lu X-CM, Mooney M, Lin Q, Steiner JP, ROSS DT, Spicer D, Guo H, Howorth P, Chen Y, Lautar S, U J-H, Kalish V, Zhang J: Efficacy of GPI 6150, in mouse models of LPS-septic shock, STZ-diabetes and MPTP-neurotoxicity. Soc Neurosci Abstr (2000) 26:1026.
32. Mazzon E, Serraino I, Li J-H, Dugo L, Caputi AP, Zhang J, Cuzzocrea S: GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an antiinflammatory effect in rat models of inflammation. Eur J Pharmacol ' (2001)415:85-94.
33. Zhang J, Lautar S, Huang S, Ramsey C, Cheung A, Li J-H: GPI 6150 prevents H,O, cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem Biophys Res Commun (2000) 278:590-598.
34. Buki KG, Bauer PI, Mendeleyev J, Hakam A, Kun E: Destabilization of Zn'° co-ordination in ADP-ribose transferase (polymerizing) by 6nltroso-1,2-benzopyrone coincidental with Inactive of polymerase but not the DNA binding function. F£BSLeff(1991)290:181-185.
35. ICOS CORPORATION (Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL): Human poly(ADP-ribose) polymerase 2 materials and methods. WO-00077179 (2000).
36. BASF AG (Kock M, Hoger T, Kroger B, Otterbach B, Lubisch W, Lemaire H-G): Poly(ADP-ribose) polymerase gene. WO-09964572 (1999).
37. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Rome LH, Kickhoefer VA): Human minor vault protein p193. US-06156879 (2000).
38. ROCKEFELLER UNIVERSITY (De Lange T, Smith S): Tankyrase, a TRF1 binding protein. WO-09964606 (1999).
39. PHARMACIA & UPJOHN SPA (Berthelsen J, Toma S, Isacchi, A): Tankyrase homolog protein (THP), nucleic acids, and methods related to the same. WO-00104326 (2001).
40. GERON CORPORATION (Morin GB, Funk WD, Pliatyszek MA): A second mammalian tankyrase. WO-00061813 (2000).
41. ICOS CORPORATION (Christenson E, Demaggio AJ, Goldman PS, McElligott DL): Tankyrase2 materials and methods. WO-00100849 (2001).
42. NEWCASTLE UNIVERSITY VENTURES LIMITED (Griffin RJ, Calvert AH, Curtin NJ, Newell DR, Golding BT): Benzamide analogs useful as PARP(ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors. US-05756510 (1993).
43. NEWCASTLE UNIVERSITY VENTURES LIMITED (Griffin RJ, Calvert AH, Curtin NJ, Newell DR, Golding BT): Benzoxazole-4-carboxamides and their use in inhibiting poly(ADP-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy. US-06015827 (2000).
44. JOHNS HOPKINS UNIVERSITY (Zhang J, Dawson VL, Dawson TM, Snyder SH): Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity. US-05587384 (1996).
45. GERON CORPORATION (West MD): Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence. US-05874444 (1999).
46. BRITISH TECHNOLOGY GROUP (Collins MKL, Farzaneh F, Shal S, Tavassoli M): Inhibition of viral infection. US-05633282 (1997).
47. CASE WESTERN RESERVE UNIVERSITY (Gerson SL, Liu L): Methoxyamine potentiation of temozolomide anti-cancer activity. WO-00112199 (2001).
48. PIERRE FABRE MEDICAMENT (Peres M, Halazy S, Perrin D, Hill B): Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine. WO-09947494 (1999).
49. N-GENE RESEARCH LABS (Nagy P, Sumegi B, Takacs K): Unsaturated hydroximic acid derivatives as PARP inhibitors. WO-00014054 (2000).
50. WARNER-LAMBERT COMPANY (Suto MJ, Turner WR, Werbel LM): Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process. US-05177075 (1993).
51. WARNER-LAMBERT COMPANY (Showalter HDH): Dihydro- and tetrahydronaphthyridines. US-05391554 (1995).
52. BASF AG (Lubisch W, Sadowski J, Kock M, Hôger T): Use of phthalazine derivatives. WO-00067734 (2000).
53. ONO PHARMACEUTICAL Co LTD (Seko T, Takeuchi J, Takahashi S, Naka M): 2H-Phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient. WO-00044726 (2000).
54. NEWCASTLE UNIVERSITY VENTURES LIMITED (Calvert AH, Curtin NJ, Newell DR, Golding BT, Griffin RJ): Quinazolinone compounds. US06156739 (2000).
55. NEWCASTLE UNIVERSITY VENTURES LIMITED (Griffin RJ, Curtin NJ, Newell DR, Golding BT): Quinazolinone compounds as chemotherapeutic agents. EP-00897915 (1999).
56. MEIJI SEIKA KAISHA LTD (Hasegawa T, Nakajima H, Kubota D, Okuma K): Poly(ADP-ribose) polymerase inhibitors consisting of pyrimidine derivatives. WO-00042025 (2000).
57. NEWCASTLE UNIVERSITY VENTURES LIMITED (Griffin RJ, Calvert AH, Curtin NJ, Newell DR, Golding BT): Benzimidazole compounds. US06100283 (2000).
58. BASF AG (Lubisch W, Kock M, Hoger T): Substituted 2phenylbenzimidazoles, the production thereof and their use. WO00026192 (2000).
59. BASF AG (Lubisch W, Kock'M, Hoger T): 2-Phenylbenzimidazoles and 2-phenylindoles and production and use thereof. WO-00029384 (2000).
60. BASF AG (Lubisch W, Kock M, Höger T, Grandel R, Muller R): Substituted benzimidazoles and their use as PARP inhibitors. WO00032579 (2000).
61. BASF AG (Lubisch W, Kock M, Hoger T, Schult S, Muller R): Cycloalkyl substituted benzimidazoles and their use as PARP inhibitors. WO-00064878 (2000).
62. BASF AG (Lubisch W, Kock M, Hoger T, Grandel R, Holzenkamp U, Schult S, Muller R): Heterocyclically substituted benzimidazotes, the production and application thereof. WO-00068206 (2000).
63. YAMANOUCHI PHARMACEUTICAL Co LTD (Takayama K, Koga Y, Masuda N, Miyazaki Y, Kimura, T, Nagashima S, Okamoto Y, Okada, Y, Takeuchi M): Benzimidazole derivatives. WO-00121615 (2001).
64. AGOURON PHARMACEUTICALS INC (Webber SE, Canan-koch SS, Tikhe JG, Thoresen LH): Tricyclic inhibitors of poly(ADP-ribose) polymerases. WO-00042040 (2000).
65. AGOURON PHARMACEUTICALS INC (Webber SE, Skalitzky DJ, Tikhe JG, Kurnpf RA, Marakovits JT, Eastman WB): Tricyclic inhibitors of poly(ADP-ribose) polymerases. WO-00116136 (2001 ).
66. GUILFORD PHARMACEUTICALS INC (Li J-H, Zhang J): Fused tricyclic compounds which inhibit PABP activity. WO-09959975 (1999).
67. GUILFORD PHARMACEUTICALS INC (U J-H, Tays KL, Zhang, J): Oxosubstituted heterocyclic compounds, therapeutic methods, and compositions for inhibiting poly(ADP-ribose) polymerase (PARP) activity. WO-09911624 (1999).
68. GUILFORD PHARMACEUTICALS INC (Li J-H, Zhang J, Jackson PF, Maclin KM): Poly(ADP-ribose) polymerase (PARP) inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage. WO-09911645 (1999).
69. GUILFORD PHARMACEUTICALS INC (Li J-H, Zhang J): Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage. WO00116137 (2001).
70. OCTAMER INC (Kun E): Methods of treating inflammation and inflammatory disease using PADPRT inhibitors. US-05908861 (1999).
71. OCTAMER INC (Kun E, Mendeleyev J, Rice WC): Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, and anti-tumor agents. US-05753647 (1998).
72. OCTAMER INC (Kun E, Mendeleyev J, Kirsten; Eva): Methods of treating cancer with aromatic nitro and nitroso compounds and their metabolites. US-06004978 (1999).
73. OCTAMER INC (Kun E): Specific inactivators of 'retroviral' (asymmetric) zinc fingers. US-05516941 (1996).
74. OCTAMER INC (Kun E, Mendeleyev J, Kirsten E): Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents. US-05464871 (1995).
75. OCTAMER INC (Kun E, Mendeleyev J): Methods of treating cancer and viral infections with 5-iodo-6-amino and 5-iodo-6-nltroso-1 2benzopyrones. US-05783599 (1998).
76. GUILFORD PHARMACEUTICALS INC (Zhang J, Serdyuk LE, Li J-H): Orthodiphenol compounds, methods and pharmaceutical compositions for inhibiting PARP. US-06201020 (2000).
77. GUILFORD PHARMACEUTICALS INC (Zhang J, lays, KL, U J-H): Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP. WO-00039104 (2000).